Pharmaceutical News

RSS

Recategorization recommendations for drug in hallucinogenic mushrooms

In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug--one with no known medical potential--to a schedule IV drug such as prescription sleep aids, but with tighter control.

26 Sep 2018

FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome

Myelo Therapeutics GmbH announced today that the US Food and Drug Administration has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 for the treatment of Acute Radiation Syndrome.

25 Sep 2018

Researchers develop molecule that makes cancer cells sensitive to radiotherapy

Researchers from Karolinska Institutet and Kancera AB have developed a molecule that makes cancer cells sensitive to radiotherapy. In a study published in Nature Communications, the researchers describe a new way to block cancer cells' ability to repair their DNA and thus stop the survival of cancer cells.

25 Sep 2018

Toxicological evaluation and dosimetry estimation of potential PET radiotracer

The SR101 N-(3-[18F]Fluoropropyl) sulfonamide ([18F]SRF101) is a Sulforhodamine 101 derivative that was previously synthesized by our group.

25 Sep 2018

Common painkiller not effective in controlling chronic pain after traumatic nerve injury

A new study out today in the Journal of Neurology finds that pregabalin is not effective in controlling the chronic pain that sometimes develops following traumatic nerve injury.

25 Sep 2018

Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US

Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.

24 Sep 2018

BetterYou receives double accolade at Janey Loves Platinum Awards 2018

Pioneering natural health company BetterYou has received two awards at the annual Janey Loves Platinum Awards 2018.

From BetterYou Ltd 24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

New spinout company to tackle drug-resistant infections with novel antibiotics

Drug-resistant infections are set to kill more people than cancer by 2050. Now a new University of Plymouth spinout company has been established to help tackle the problem - by developing new antibiotics and bringing them to market.

24 Sep 2018

Greater awareness of science can help public overcome fear of vaccines

The increasing distrust in vaccinations has triggered an extensive scientific and public debate over whether or not it is useful, safe and ethical to vaccinate children today.

24 Sep 2018

New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer

A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus-related head and neck cancer.

24 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

As states try to rein in drug spending, feds slap down one bold Medicaid move

States serve as “laboratories of democracy,” as U.S. Supreme Court Justice Louis Brandeis famously said. And states are also labs for health policy, launching all kinds of experiments lately to temper spending on pharmaceuticals.

21 Sep 2018

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

Ipsen announced today that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, provided a positive opinion for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib.

21 Sep 2018

UAB researchers study dysfunction of the immune system associated with NSAID carprofen

Non-steroidal anti-inflammatory drugs, or NSAIDs, are commonly used as inflammation blockers worldwide. However, recent clinical data show these painkillers can have serious side effects that create some risk of heart attacks, strokes, and kidney or heart failure.

21 Sep 2018

New naturally occurring antibiotic found effective against Mycobacterium tuberculosis

A naturally occurring antibiotic called kanglemycin A is effective against Mycobacterium tuberculosis, the bacteria that cause tuberculosis, even in drug-resistant strains, according to an international team of researchers who used chemistry, molecular biology, microbiology, and X-ray crystallography to show how the compound maintains its activity.

21 Sep 2018

Pfizer’s 20vPnC vaccine receives Breakthrough Therapy designation from FDA

Pfizer Inc. announced today that its 20-Valent Pneumococcal Conjugate Vaccine candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. Pfizer expects to start Phase 3 trials in a few months.

20 Sep 2018

LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.

20 Sep 2018

Pharmaceutical News

Recategorization recommendations for drug in hallucinogenic mushrooms

FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome

Researchers develop molecule that makes cancer cells sensitive to radiotherapy

Toxicological evaluation and dosimetry estimation of potential PET radiotracer

Common painkiller not effective in controlling chronic pain after traumatic nerve injury

Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US

BetterYou receives double accolade at Janey Loves Platinum Awards 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

New spinout company to tackle drug-resistant infections with novel antibiotics

Greater awareness of science can help public overcome fear of vaccines

New therapeutic vaccine helps immune cells fight HPV-related head and neck cancer

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

As states try to rein in drug spending, feds slap down one bold Medicaid move

CHMP provides positive opinion to Cabometyx for previously-treated patients with hepatocellular carcinoma

UAB researchers study dysfunction of the immune system associated with NSAID carprofen

New naturally occurring antibiotic found effective against Mycobacterium tuberculosis

Pfizer’s 20vPnC vaccine receives Breakthrough Therapy designation from FDA

LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News